Key Financial Figures - Standalone (₹ in Million)

Quarter ended June 30, 2026:

  • Revenue from operations: ₹58,813.0
  • Total income: ₹58,813.0
  • Total expenses: ₹43,633.2
  • Profit before exceptional items and tax: ₹15,179.8
  • Exceptional items: ₹315.3
  • Profit before tax: ₹14,864.5
  • Tax expense: ₹3,792.4 (including tax credit on exceptional items of ₹79.3)
  • Profit for the period: ₹11,151.4
  • Other comprehensive income: ₹1,443.3
  • Total comprehensive income: ₹12,594.7

Comparative Figures (Quarter ended June 30, 2025):

  • Profit before exceptional items and tax: ₹14,639.0
  • Exceptional items: ₹2,876.4
  • Profit before tax: ₹11,762.6
  • Tax expense: ₹5,317.1 (including exceptional tax credit of ₹1,005.1)
  • Profit for the period: ₹7,450.6

Key Financial Figures - Consolidated (₹ in Million)

Quarter ended June 30, 2026:

  • Revenue from operations: ₹152,998.8
  • Total income: ₹160,235.0
  • Total expenses: ₹117,206.0
  • Profit before exceptional items and tax: ₹43,029.0
  • Exceptional items: ₹2,040.9
  • Profit before tax: ₹40,988.1
  • Tax expense: ₹11,974.4 (including exceptional tax credit of ₹94.3)
  • Profit before share of profit/loss of associates and joint venture: ₹29,108.0
  • Share of profit/loss of associates and joint venture: ₹(95.7)
  • Net profit after taxes but before non-controlling interests: ₹29,012.3
  • Non-controlling interests: ₹64.4
  • Net profit after taxes: ₹28,947.9
  • Other comprehensive income: ₹15,091.5
  • Total comprehensive income: ₹44,103.8
  • Earnings per share (Basic and Diluted): ₹12.1

Comparative Figures (Quarter ended June 30, 2025):

  • Net profit after taxes: ₹22,786.3
  • Earnings per share: ₹9.5

Exceptional Items

Standalone (Q1 FY27):

  • ₹315.3 million incremental cost related to reassessment of employee compensation structures under New Labour Codes framework, with related tax credit of ₹79.3 million.

Consolidated (Q1 FY27):

  • ₹2,040.9 million exceptional costs comprising:
  • ₹1,670.0 million for due diligence, legal, filing fees, and other acquisition-related costs for Organon & Co. acquisition
  • ₹370.9 million related to New Labour Codes reassessment, with tax credit of ₹94.3 million

Segment Performance

  • India Formulations: ₹54,748.9 million (16% YoY growth), representing 36.1% of total sales
  • US Formulations: ₹40,419.1 million (US$427 million, down 9.7% YoY), representing 26.6% of total sales
  • Emerging Markets Formulations: ₹29,456.3 million (US$311 million, up 4.2% YoY), representing 19.4% of total sales
  • Rest of World Formulations: ₹20,685.8 million (US$218 million), representing 13.6% of total sales
  • API Sales: ₹5,972.3 million (10.5% YoY growth)
  • Global Innovative Medicines: US$351 million (12.8% YoY growth), representing 21.9% of total sales

R&D Investment

  • Total R&D expenditure: ₹8,263.5 million (5.4% of sales)
  • Revenue R&D: ₹8,076.6 million
  • Capital R&D: ₹186.9 million

Strategic Updates

  • The definitive agreement to acquire all outstanding shares of Organon & Co. for cash payment of US$14.00 per share (enterprise valuation of US$11.75 billion) is subject to approvals and closing conditions. Organon shareholders have approved the acquisition, which is on track to close in early 2027.
  • The company exercised the option under Section 115BAA of the Income-tax Act, 1961, for FY 2026-27, resulting in a concessional tax rate of 25.168% and a net credit to tax expense of ₹1,030.0 million for the quarter ended March 31, 2026.
  • The National Company Law Tribunal approved the Composite Scheme of Arrangement for amalgamation of five wholly-owned subsidiaries with appointed date of April 1, 2023.

Capital Structure

  • Paid-up equity share capital: ₹2,399.3 million (face value ₹1 each)
  • No change in share capital during the quarter

Exchange Rates

  • US$1 = ₹94.70 (Q1 FY27 average)
  • US$1 = ₹85.56 (Q1 FY26 average)

Forward-looking Statements

The document contains forward-looking statements about the company's objectives, projections, estimates, and plans. Actual results may differ materially from these statements.